These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 14685645

  • 21. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M.
    J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Citalopram plus reboxetine in treatment-resistant depression.
    Devarajan S, Dursun SM.
    Can J Psychiatry; 2000 Jun; 45(5):489-90. PubMed ID: 10900531
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
    Dubini A, Bosc M, Polin V.
    Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
    Nelson JC, Portera L, Leon AC.
    Biol Psychiatry; 2005 Jun 15; 57(12):1535-42. PubMed ID: 15953490
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
    Papakostas GI, Nelson JC, Kasper S, Möller HJ.
    Eur Neuropsychopharmacol; 2008 Feb 15; 18(2):122-7. PubMed ID: 17719752
    [Abstract] [Full Text] [Related]

  • 37. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M.
    J Clin Psychiatry; 2002 Jan 15; 63(1):31-7. PubMed ID: 11838623
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial.
    Green A, Crawford A, Button KS, Wiles N, Peters TJ, Nutt D, Lewis G.
    J Affect Disord; 2014 Jul 15; 163():40-6. PubMed ID: 24836086
    [Abstract] [Full Text] [Related]

  • 40. The antidepressant efficacy of reboxetine in patients with severe depression.
    Montgomery S, Ferguson JM, Schwartz GE.
    J Clin Psychopharmacol; 2003 Feb 15; 23(1):45-50. PubMed ID: 12544375
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.